Obesity-news.com THE LATEST IN OBESITY RESEARCH AND WEIGHTLOSS DRUG DEVELOPMENT     Join our list More information      Volume 10, Issue 1 January 2006 WINTER CONFERENCE UPDATE WEIGHT LOSS AND DIABETES DRUGS January 25, 2006 -- Editor's note: Below are transcript summaries of preclinical and clinical weight loss and diabetes drugs presented at company press conferences and the recent Rodman Renshaw conference. These are not verbatim transcripts, but transcript summaries which have been edited for readability. Redundant content has also been edited out. Because these articles are long and contain multiple graphics, each one has been published in a separate document. Contents Company Conference Alizyme Cetilistat (ATL-962): Phase I results. Rodman Renshaw Arena APD356: Phase II results. 19AJ agonists: Preclinical. ChemGenex Preclinical diabetes and obesity pipeline. Cytrx RIP140: Preclinical. Manhattan Oleoyl-estrone: Phase I results. Metabolex Metaglidasen: Phase II results. Metabolic AOD9604: Phase II results. Neurogen MCH 1: Preclinical. Subcription Information A one year on-line subscription to Obesity-news is $104.00. Send check or money order, in US currency to: Obesity-news, PO Box 19316, Alexandria, VA 22320-0316. Or subscribe or renew on-line using American Express, Discover, VISA or Mastercard through our secure server. Home|Subscribe|Archives|Drug info|Contact|Media & Links|Site index|FAQs|Doctors/meetings|Admin Obesity-news is a publication of Hirsch Communications. An on-line subscription is $104.00 per year, payable in advance by check, money order, American Express, Discover, VISA or Mastercard. Subscribing is simple using our secure on-line subscription form. Obesity-news also accepts fax orders at 703/960-7462 and mail orders at PO Box 19316, Alexandria, VA 22320-0316. Copyright 1997-2008, all rights reserved. IMPORTANT: All information in this publication is believed to be accurate and true. Publisher is not liable for omissions or inaccuracies. Information in this newsletter is for educational purposes only and should not be construed as medical advice, or be used in lieu of consultation with a health care provider.